Explore evidence

50 %The mortality rate of cryptococcal meningitis was 50%.

Côte d'Ivoireméningite cryptococciqueobserved 2008 to 2011published 2017Journal de mycologie medicaleeurope_pmcdocument of 11 observations

1.42 per_100_person_monthsDuring the pre-intervention period, the incidence rates were 1.42 cases per 100 person-months in the LLIN-alone control group.

Côte d'IvoirepaludismeHAL · Unilimdocument of 54 observations

1.07 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 1.07 (95% CI = 0.01–4.91) at CD4+ counts >500/mm³ compared to HBsAg-negative individuals.

Côte d'Ivoirehépatite B · VIH/sidapublished 2021Antiviral therapyeurope_pmcdocument of 4 observations

0.98 %The sporozoite infection prevalence was 0.98% in the LLIN-only group and 0.5% in the LLIN + BTI group.

Côte d'IvoirepaludismeHAL · Unilimdocument of 54 observations

2.7 %Among 879 participants in the Temprano randomized control trial, 24 (2.7%) had hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥ 2,000 IU/ml.

Côte d'Ivoirehépatite Bobserved 2008 and 2015published 2021Journal of viral hepatitiseurope_pmcdocument of 5 observations

46 casesForty-six cases of cryptococcal meningitis were identified, representing 2.5% of hospitalizations.

Côte d'Ivoireméningite cryptococciqueobserved 2008 to 2011published 2017Journal de mycologie medicaleeurope_pmcdocument of 11 observations

The prevalence of symptomatic malaria cases decreased significantly with age.

Côte d'IvoirepaludismeHAL · Unilimdocument of 122 observations

90.3 %28 (90.3%) of the HIV-2 patients were on PI-based ART-regimen at enrolment.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

46 %The proportion of Pfcrt-76T mutant allele was 46% in Abobo, Ivory Coast.

Côte d'Ivoirepaludismeobserved 2009published 2019Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument of 5 observations

0.57 sensitivityA ≥ 1.0 log10 IU/mL drop in qHBsAg at month 12 had sensitivity of 0.57 and specificity of 1.00 for predicting HBsAg seroclearance at month 36.

Côte d'Ivoirehépatite Bobserved month 36published 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156

All three patients had received antiretroviral therapy for more than four years, including lopinavir/ritonavir for more than eight months.

Côte d'IvoireVIH/sidapublished 2009Antiviral therapyeurope_pmcdocument of 11 observations

82.1 %82.1% of HIV-infected female sex workers in Abidjan, Côte d'Ivoire were on antiretroviral therapy.

Côte d'IvoireVIH/sidaobserved 2013published 2015BMC oral healtheurope_pmcdocument of 7 observations

245 patientsOf 245 patients followed for up to 3 years in a cohort of HIV-infected patients of sub-Saharan African origin, the incidence of metabolic syndrome, insulin resistance, and lipodystrophy was observed.

Côte d'IvoireVIH/sidapublished 2015AIDS research and human retroviruseseurope_pmcdocument of 7 observations

86.9 %Of 237 HIV-infected patients from two clinical trials, 206 (86.9%) tested positive for hepatitis B surface antigen (HBsAg) using MiniVidas® and had validated serological tests using Architect.

Côte d'Ivoirehépatite B · VIH/sidapublished 2015Diagnostic microbiology and infectious diseaseeurope_pmc

80 %The proportion of HIV-infected patients reaching CD4+ T cell counts >350/mm³ after six months of ART was 80.0% in the HBV coinfection with low HBV-DNA replication group.

Côte d'IvoireHIV-hepatitis B virus coinfectionpublished 2018AIDS research and human retroviruseseurope_pmcdocument of 4 observations

Among 791 HIV-infected patients in West Africa, HBsAg positivity was 7.9% in HIV-1 patients, 7.2% in HIV-1&2 dually reactive patients, and 9.4% in HIV-2 patients.

Côte d'Ivoirehépatite B · VIH/sidaobserved 2012published 2017BMC infectious diseaseseurope_pmcdocument of 7 observations

9.5 per_100_person_yearsIn patients with pre-ART CD4 cell count 200–349 cells/μL, incidence of severe morbidity was 9.5 per 100 person-years.

Côte d'IvoireVIH/sidapublished 2007AIDS (London, England)europe_pmcdocument of 9 observations

159 per_100000In Côte d'Ivoire, the incidence of tuberculosis was 159 per 100,000 people.

Côte d'Ivoiretuberculosepublished 2017The Lancet. Global healtheurope_pmcdocument of 6 observations

2.1 %Salmonella enterica Paratyphi was detected in 2.1% of febrile people in Côte d'Ivoire.

Côte d'IvoireSalmonella enterica Paratyphipublished 2021Travel medicine and infectious diseasePubMeddocument of 25 observations

69 %Cotrimoxazole led to a 69% reduction in the risk of malaria.

Côte d'Ivoirepaludismepublished 2017Tropical medicine & international health : TM & IHeurope_pmcdocument of 4 observationsDOI 10.1111/tmi.12919

10 childrenThe study included 10 children and 89 adolescents victims of rape in Abidjan between 2000 and 2013.

Côte d'IvoireVIH/sidaobserved 2000-2013published 2015Medecine et maladies infectieuseseurope_pmcdocument of 3 observations

12 %Among HIV-infected adults interviewed, 12% with more than 500 CD4+ cells/μl had a seronegative partner and should be recommended antiretroviral treatment (ART).

Côte d'IvoireVIH/sidapublished 2014AIDS (London, England)europe_pmcdocument of 5 observations

25.9 %The most frequently reported countries of contamination were Ivory Coast (25.9%), Democratic Republic of the Congo (24.1%) and Cameroon (13.2%).

Côte d'IvoirepaludismeHAL · Unilimdocument of 123 observations

0.8 rate_ratioIn Côte d'Ivoire, test positivity rates reported from DHIS2 declined significantly more in study than control facilities after study onset, with a rate ratio of 0.80 (95% CI 0.76, 0.84).

Côte d'Ivoirepaludismeobserved 2023published 2025Malaria journalPubMeddocument of 5 observations

27 %For children living with HIV, AIDS-related illnesses accounted for 27% of hospital admissions.

Côte d'IvoireAIDS-related illnessespublished 2015The lancet. HIVeurope_pmcdocument of 8 observations